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Background: The management of chronic kidney disease–mineral and bone disorder requires the
assessment of bone turnover, which most often is based on parathyroid hormone (PTH) concentration, the
utility of which remains controversial.
Study Design: Cross-sectional retrospective diagnostic test study.
Setting & Participants: 492 dialysis patients from Brazil, Portugal, Turkey, and Venezuela with prior bone
biopsy and stored (220C) serum.
Index Tests: Samples were analyzed for PTH (intact [iPTH] and whole PTH), bone-specific alkaline
phosphatase (bALP), and amino-terminal propeptide of type 1 procollagen (P1NP).
Reference Test: Bone histomorphometric assessment of turnover (bone formation rate/bone surface [BFR/
BS]) and receiver operating characteristic curves for discriminating diagnostic ability.
Results: The biomarkers iPTH and bALP or combinations thereof allowed discrimination of low from nonlow
and high from nonhigh BFR/BS, with an area under the receiver operating characteristic curve . 0.70
but , 0.80. Using iPTH level, the best cutoff to discriminate low from nonlow BFR/BS was ,103.8 pg/mL, and
to discriminate high from nonhigh BFR/BS was .323.0 pg/mL. The best cutoff for bALP to discriminate low
from nonlow BFR/BS was ,33.1 U/L, and for high from nonhigh BFR/BS, 42.1 U/L. Using the KDIGO practice
guideline PTH values of greater than 2 but less than 9 times the upper limit of normal, sensitivity and specificity
of iPTH level to discriminate low from nonlow turnover bone disease were 65.7% and 65.3%, and to
discriminate high from nonhigh were 37.0% and 85.8%, respectively.
Limitations: Cross-sectional design without consideration of therapy. Potential limited generalizability with
samples from 4 countries.
Conclusions: The serum biomarkers iPTH, whole PTH, and bALP were able to discriminate low from nonlow
BFR/BS, whereas iPTH and bALPwere able to discriminate high from nonhigh BFR/BS. Prospective studies are
required to determine whether evaluating trends in biomarker concentrations could guide therapeutic decisions.
Am J Kidney Dis. 67(4):559-566. ª 2016 by the National Kidney Foundation, Inc.
INDEXWORDS: Sensitivity and specificity; alkaline phosphatases; bone-specific alkaline phosphatase (bALP;
BSAP); bone histomorphometry; chronic kidney disease–mineral bone disorder (CKD-MBD); parathyroid
hormone (PTH); procollagen type 1 N propeptide (P1NP); renal osteodystrophy.Editorial, p. 535hronic kidney disease (CKD) is a signiﬁcantC public health problem, afﬂicting w11% of the
American adult population1 with a similar prevalence
worldwide.2Disturbances ofmineralmetabolism,which
occur in nearly all patients with CKD stages 3 to 5D, are
associated with bone loss and fractures, cardiovascular
disease, inﬂammation, abnormal immune function, and
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ciation with extraosseous calciﬁcations, have been
topics of great interest and controversy.4-8
In 2006, KDIGO (Kidney Disease: Improving
Global Outcomes), an international initiative with a
key mission of developing clinical practice guidelines
concerning CKD, published a position statement pro-
posing a new approach to classifying bone and mineral
disorders termed CKD–mineral and bone disorder
(CKD-MBD).9 This was deﬁned as a systemic disor-
der, with renal osteodystrophy being redeﬁned as oneMedicine and Roudebush Veterans Administration Hospital,
Indianapolis, IN.
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Sprague et alof the components of CKD-MBD, and the recom-
mendation was to only use this term to delineate bone
histopathologic ﬁndings. The gold standard for the
diagnosis and speciﬁc classiﬁcation of renal osteo-
dystrophy is a bone biopsy with bone histo-
morphometry.9,10 There is heterogeneity of histologic
abnormalities observed in patients with CKD,11 and
patients may develop different lesions as CKD pro-
gresses. The classic description of the histologic
abnormalities includes hyperparathyroid bone disease,
adynamic bone disease, osteomalacia, and mixed
uremic osteodystrophy.11-14 The KDIGO consensus
conference agreed on a new classiﬁcation of renal
osteodystrophy that addresses the most important bone
abnormalities, which include changes in bone turnover
(T), mineralization (M), and volume (V).9 The TMV
classiﬁcation is consistent with the classically used
classiﬁcation system.11-14
The main focus on renal osteodystrophy has been to
assess bone disease based on bone turnover, from low to
high.Because bone turnover is a function in large part of
the degree of hyperparathyroidism, circulating para-
thyroid hormone (PTH) levels have traditionally been
used as a surrogate indicator of bone turnover. Intact
PTH (iPTH), together with PTH ratio, has been studied
for the diagnosis of bone turnover in dialysis pa-
tients,15,16 and differences between whites and blacks
have been shown.16However, the assay for determining
PTH ratio is not widely available. Together with serum
calcium, phosphorus, and total alkaline phosphatases or
bone-speciﬁc alkaline phosphatase (bALP), PTH levels
are used to guide the pharmacologic treatment of CKD-
MBD. However, using PTH levels from random serum
samples as the primary criteria for deﬁning and moni-
toring bone turnover alterations in CKD is an over-
simpliﬁcation of the complexity that governs this
process. In addition, differences in intermethod (assay)
PTH standards, variability, and reference ranges17-19
have led to confusion about the use of PTH as a bone
biomarker. Additional bone biomarkers have also been
evaluated for their predictive value in assessing renal
osteodystrophy, but sample sizes of these studies were
small and inconclusive.20,21 Information evaluating
renal bone disease with the currently used PTH assays
alone or in combinationwith other bone biomarkers and
the utility of classifying renal osteodystrophy with the
TMV system are limited.22,23 Thus, in order to better
deﬁne the relative diagnostic value of various circu-
lating biomarkers that are currently in clinical use alone
or as a panel, KDIGO led an international consortium in
a cross-sectional retrospective diagnostic test study.
The goal of this study was to determine the predictive
value of serum levels of PTH (determined by both iPTH
and whole PTH assays), bALP, and amino-terminal
propeptide of type 1 procollagen (P1NP) as markers
of bone turnover.560
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Study Population and Data Collection
Data and serum samples were obtained from clinical programs
in Brazil, Portugal, Turkey, and Venezuela. All patients from the 4
study sites who had been treated with dialysis for at least 3 months
and had a reported histomorphometric analysis of a bone biopsy
specimen and stored serum drawn within 30 days of the acquisi-
tion of the bone biopsy specimen were included in the study. All
blood specimens were obtained from November 1993 through
June 2007 and stored frozen at below 220C until analyzed in
November 2008. Additional data collected included demographics
(age, sex, ethnicity, country of origin, and dialysis modality and
vintage), biopsy technique, health history (cause of CKD, time
since ﬁrst diagnosis of CKD, history of diabetes mellitus, para-
thyroidectomy, or previous kidney transplantation), biochemical
parameters (calcium, phosphorus, and iPTH), and treatment in-
formation (vitamin D, type of vitamin D, phosphate binder, and
type of binder) at the time of the biopsy (Table 1).
Serum Biochemistry
All serum biomarkers were measured by a single central
laboratory (Nordic Biochemical Research Laboratory, Herlev,
Denmark). Reference ranges for P1NP were 13.9 to 85.5 ng/mL for
men, 15.1 to 58.6 ng/mL for premenopausal women, and 20.3 to
76.3 ng/mL for postmenopausal women. The laboratory measured
iPTH using a chemiluminescence immunoassay on a Roche Elec-
sys 2010 Analyzer; this assay detects both iPTH and a fragment
containing amino acids 7 to 84; the reference range is 15.0 to
65.0 pg/mL. The laboratory measured whole PTH with an immu-
noradiometric assay kit from Scantibodies Laboratories; this assay
is speciﬁc for PTH isoforms containing amino acids 1 to 84, and the
reference range is 6.0 to 32.0 pg/mL. bALP was measured by an
immunoassay from Quidel (reference range, 15.0-41.3 U/L for
men, 14.2-42.7 U/L for postmenopausal women, and 11.6-29.6 U/
L for premenopausal women). All serum samples were stored at
below220C for various periods. Specimen collection and storage
condition characteristics, temperature settings (280C vs 220C),
and specimen age were recorded.
Bone Biopsy and Histomorphometry
Histologic interpretation of bone biopsy specimens were com-
pleted at the Bone Diagnostic and Research Laboratory, University
of Kentucky, Lexington (for biopsies from patients from Turkey);
Federal University of São Paulo, São Paulo, Brazil; University of
São Paulo Renal Physiopathology Laboratory, São Paulo, Brazil
(for biopsies from Brazil and Portugal); and University Hospital of
Caracas, Caracas, Venezuela (for biopsies from Venezuela) The
histomorphometric parameter used for analysis of bone turnover is
bone formation rate/bone surface (BFR/BS). Each laboratory used
their normative data to classify BFR/BS as either low, normal, or
high (Table S1, available as online supplementary material).
Statistical Analysis
Descriptive statistics were presented as mean 6 standard devi-
ation and median; frequency and percentage were presented for
data with tabulation. Correlations between biomarkers were
assessed by computing a Spearman correlation coefﬁcient. Anal-
ysis of variance (ANOVA) or nonparametric counterpart Kruskal-
Wallis test was used to detect between-group difference; post
hoc pairwise comparison was Bonferroni adjusted (for ANOVA) or
by Terpstra permutation test (for nonparametric test). Logistic
regression analysis was conducted to derive the area under the
receiver operating characteristic (ROC) curve (AUROC) to deter-
mine the diagnostic ability for bone turnover of the biomarkers.
AUROC . 0.7 is very good, .0.8 is excellent, and .0.9 isAm J Kidney Dis. 2016;67(4):559-566
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Table 1. Patient Characteristics at Time of Bone Biopsy
Total Portugal Venezuela Brazil Turkey
No. analyzed 492 89 114 156 133
Female sex 218 (44.3) 35 (39) 52 (45.6) 54 (34.6) 77 (57.9)
Age, y 49.5 6 15.1 48.0 6 14.1 40.36 14.9 49.5 6 12.9 57.4 6 14.0
Dialysis vintage, y 4.746 3.7 7.27 6 4.9 4.39 6 3.3 3.896 2.7 4.156 3.3
Peritoneal dialysis 7 (1.4) 1 (1) 6 (5.3) 0 (0) 0 (0)
Cause of ESRD
Hypertension 112 (22.8) 22 (25) 27 (23.7) 45 (28.8) 18 (13.5)
Glomerulonephritis 78 (15.8) 20 (23) 21 (18.4) 26 (16.7) 11 (13.5)
Diabetic nephropathy 46 (9.3) 0 (0) 6 (5.3) 19 (12.2) 21 (15.8)
Chronic interstitial nephritis 33 (6.7) 11 (12) 11 (9.6) 9 (5.8) 2 (1.5)
Polycystic kidney disease 28 (5.7) 9 (10) 3 (2.6) 7 (4.5) 9 (6.8)
Other/unknown 193 (39.2) 25 (28) 46 (40.4) 50 (32.1) 72 (54.1)
Serum calcium, mg/dL 9.51 6 1.03 9.79 6 0.94 8.866 1.10 10.126 0.76 9.12 6 0.81
Serum phosphorus, mg/dL 5.77 6 1.93 6.15 6 1.95 4.90 6 2.0 6.63 6 1.78 5.13 6 1.53
Serum iPTH, pg/mL 542 6 642 8126 698 9426 912 390 6 330 216 6 247
History of diabetes 58 (11.8) 1 (1) 12 (10.5) 21 (13.5) 24 (18.0)
History of kidney transplantation 46 (9.3) 11 (12) 16 (14.0) 11 (7.0) 8 (6.0)
Parathyroidectomy 5 (1.0) 1 (1) 2 (1.8) 0 (0) 2 (1.5)
Vitamin D therapya 143 (29.1) 40 (45) 35 (30.7) 67 (42.9) 1 (0.7)
Phosphate binders
Calcium-based 379 (77.0) 56 (63) 103 (90.4) 111 (71.2) 109 (82.0)
Aluminum salt 52 (10.6) 44 (49) 5 (4.4) 3 (1.9) 0 (0)
Sevelamer HCl 42 (8.5) 0 (0) 0 (0) 41 (26.3) 1 (0.7)
Corticosteroids 24 (4.9) 3 (3) 21 (18.4) 0 (0) 0 (0)
Immunosuppressives 20 (4.1) 3 (3) 17 (14.9) 0 (0) 0 (0)
Note: Unless otherwise indicated, values for categorical variables are given as number (percentage); values for continuous vari-
ables, as mean 6 standard deviation. None of the study participants were receiving cinacalcet, lanthanum carbonate phosphate
binder, or hormone replacement therapy at the time of the biopsy. Only 1 patient (Venezuela) was prescribed a bisphosphonate at the
time of the biopsy.
Abbreviations: ESRD, end-stage renal disease; iPTH, intact parathyroid hormone.
aCalcitriol was the only prescribed vitamin D therapy in the study participants.
Eligible patients
n = 610
Excluded Patients
n = 83 exclusions were due to 
inadequate volume of blood 
specimens to complete all 4 required 
assays
n = 35 exclusions for inadequate bone 
biopsy data
Patients included in analysis
n = 492
Bone Turnover as Classiϐied 
by Histomorphometry
Figure 1. Flow diagram of patient samples.
Bone Marker and Bone Histology Correlationdistinguished.24 The best cutoff on the AUROC curve was deter-
mined by Youden J statistic. The optimal cutoff is the threshold that
maximizes the distance to the identity (diagonal) line.25 P , 0.05
is regarded as statistically signiﬁcant. SAS, version 9.2 (SAS
Institute Inc), and R version 3.1.1 (R Foundation for Statistical
Computing) were used to carry out all statistical analyses.
RESULTS
Study Participants
Of610 dialysis patient samples initially identiﬁed for
this analysis, 492 had an adequate quantity of stored
serum and biopsy data to be included in analyses
(Fig 1). Basic demographic data for the 492 dialysis
patients from Brazil, Portugal, Turkey, and Venezuela
who underwent bone biopsy and had simultaneous
serum samples obtained and stored frozen are presented
in Table 1. There was a strong correlation (r 5 0.927;
P , 0.001) between serum PTH values determined
with iPTH and whole PTH assays (Figs 2 and S1), with
whole PTH levels beingw40% of iPTH values.
Biomarker Assessment of Bone Turnover
Bone turnover based on BFR/BS reference values
of the participating laboratories was deﬁned as being
low, normal, or high. There was a positive correlationAm J Kidney Dis. 2016;67(4):559-566
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(Table S2). Of 492 patients analyzed, there were 289
with low bone turnover (59%), 120 with normal bone561
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Figure 2. Correlation of parathyroid hormone (PTH) assays.
The correlation between serum intact (iPTH) and serum whole
PTH (wPTH) values measured by the central laboratory. There
was a strong correlation (r 5 0.927; 95% confidence interval
[CI], 0.897-0.950; P, 0.001, n5 492) between serum PTH
values determined with iPTH and wPTH assays.
Sprague et alturnover (24%), and 83 with high bone turnover
(17%). Levels of iPTH, whole PTH, bALP, and P1NP
stratiﬁed by bone turnover (low, normal, or high) are
shown in Table 2.
ROC curves were developed to determine whether
the bone biomarkers could discriminate between
clinically important differences of low bone turnover
from nonlow turnover and high bone turnover from
nonhigh turnover (Table 3). To predict low turnover,
these data suggest that the optimal cutoff value of
iPTH of ,103.8 pg/mL would have an AUROC of
0.701, whereas the optimal cutoff of whole
PTH, 48.0 pg/mL would correspond to AUROC of
0.712. bALP level , 33.1 U/L would have an
AUROC of 0.757 to predict low bone turnover,
whereas an optimal P1NP value , 498.9 ng/mL did
not adequately predict low bone turnover
(AUROC5 0.650). To predict high turnover, an
optimal iPTH level would be .323.0 pg/mL with an
AUROC of 0.724, whereas the whole PTH assay did
not adequately predict high bone turnover
(AUROC5 0.678). bALP level . 42.1 U/L would
have an AUROC of 0.711 to predict high boneTable 2. Discrimination of Bone Tu
Low
(n 5 289)
Normal
(n 5 120
iPTH, pg/mL 68.2 [23.2-186.3] 180.7 [50.0-7
wPTH, pg/mL 24.2 [8.1-68.4] 81.4 [27.3-2
bALP, U/L 28.2 [18.0-46.2] 33.7 [60.0-1
P1NP, ng/mL 348.3 [183.1-599.6] 483.7 [207.1-
Note: Values are given as median [interquartile range]. Assignmen
assessment of bone formation rate/bone surface. Normal values f
P values for all markers , 0.001.
Abbreviations: bALP, bone-specific alkaline phosphatase; iPTH, i
type 1 procollagen; wPTH, whole parathyroid hormone.
562
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have an AUROC of 0.743 to predict high bone
turnover (Table 3).
The combination of iPTH and bALP levels gener-
ated slightly better ability to discriminate high from
nonhigh bone turnover (AUROC 5 0.718) than
whole PTH and bALP levels. Discrimination between
low and nonlow bone turnover was also slightly
improved with the combination of iPTH and bALP or
whole PTH and bALP levels in combination
(AUROCs 5 0.718 and 0.743, respectively). Thus,
although there were differences between bone turn-
over and iPTH, whole PTH, and bALP levels across
bone turnover classiﬁcations, no biomarker singly or
in combination was robust enough to diagnose low,
normal, and high bone turnover.
Country, calcium use, and age were found to be
signiﬁcantly associated with BFR/BS discrimination
of low versus nonlow bone turnover in a univariate
model. However, adjusting for these parameters in
multivariate analysis, both iPTH and whole PTH
levels remained signiﬁcantly predictive (P , 0.001)
to discriminate low from nonlow bone turnover
(Table S3). Country, diabetes as primary diagnosis,
use of non–calcium-based phosphate binder, no use of
phosphate binder, and dialysis vintage (years) were
found to be signiﬁcantly associated with BFR/BS
discrimination of high versus nonhigh bone turnover
in a univariate model (all P , 0.05). However, after
adjusting for these factors in multivariate analysis,
both iPTH and whole PTH levels remained signiﬁ-
cantly predictive (P , 0.001) to discriminate high
from nonhigh bone turnover (Table S4).
Clinical practice guidelines have recommended the
use of ranges of iPTH in order to optimize therapies.
Thus, in addition to evaluating the diagnostic accuracy
of iPTH with or without bALP level as a continuous
measure, we also assessed the diagnostic utility of
using the iPTH stratiﬁcation scheme based on the
NKF-KDOQI (National Kidney Foundation2Kidney
Disease Outcomes Quality Initiative) iPTH target
level (150-300 pg/mL) and the KDIGO iPTH or whole
PTH level range (2-9 times the upper limit of normal),rnover by Serum Biochemistry
)
High
(n 5 83) Reference Range
17.9] 382.6 [139.5-865.5] 15.0-65.0
99.0] 106.0 [36.7-369.4] 6.0-32.0
18.0] 63.3 [42.3-116.8] 11.6-42.7
786.4] 787.0 [523.7-992.2] 13.9-85.5
t to low, normal, and high bone turnover categories was based on
or each laboratory are in Table S1. Terpstra permutation test
ntact parathyroid hormone; P1NP, amino-terminal propeptide of
Am J Kidney Dis. 2016;67(4):559-566
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Table 3. AUROCs of Circulating Bone Biomarkers to
Distinguish High and Low Bone Turnover From Nonhigh and
Nonlow Bone Turnover as Assessed by BFR/BS
Blood Sample
Marker N AUROC (95% CI)
Best
Cutoff
Low vs Nonlow
iPTH, pg/mL 280 vs 196 0.701 (0.653-0.750) 103.8
wPTH, pg/mL 260 vs 180 0.712 (0.662-0.761) 48.0
bALP, U/L 273 vs 190 0.757 (0.713-0.801) 33.1
P1NP, ng/mL 280 vs 1,197 0.650 (0.599-0.701) 498.9
Combined iPTH 1
bALP
272 vs 188 0.718 (0.670-0.767) NA
Combined
wPTH 1 bALP
257 vs 174 0.743 (0.695-0.790) NA
High vs Nonhigh
iPTH, pg/mL 81 vs 395 0.724 (0.663-0.786) 323.0
wPTH, pg/mL 75 vs 365 0.678 (0.611-0.746) 61.4
bALP, U/L 77 vs 386 0.711 (0.655-0.767) 42.1
P1NP, ng/mL 81 vs 396 0.743 (0.689-0.797) 621.1
Combined iPTH 1
bALP
76 vs 384 0.718 (0.658-0.779) NA
Combined
wPTH 1 bALP
72 vs 359 0.691 (0.628-0.725) NA
Abbreviations: AUROC, area under the receiver operating
characteristic curve; bALP, bone-specific alkaline phosphatase;
BFR/BS, bone formation rate/bone surface; CI, confidence in-
terval; iPTH, intact parathyroid hormone; NA, not available;
P1NP, amino-terminal propeptide of type 1 procollagen; wPTH,
whole parathyroid hormone.
Table 4. Sensitivity and Specificity of PTH Using Cutoffs of
Published Clinical Practice Guidelines to Predict Bone Turnover
as Assessed by BFR/BS
Sensitivity Specificity
NKF-KDOQI guideline cutoffs
iPTH , 150 pg/mL for low turnover 68.6% 61.2%
iPTH . 300 pg/mL for high turnover 58.0% 77.7%
KDIGO guideline cutoffs
iPTH , 23ULN for low turnover 65.0% 67.3%
iPTH . 93ULN for high turnover 37.0% 85.8%
KDIGO guideline cutoffs
wPTH , 23ULN for low turnover 73.5% 56.7%
wPTH . 93ULN for high turnover 30.7% 87.9%
Abbreviations: BFR/BS, bone formation rate/bone surface;
iPTH, intact parathyroid hormone; KDIGO, Kidney Disease:
Improving Global Outcomes; NKF-KDOQI, National Kidney
Foundation–Kidney Disease Outcomes Quality Initiative; PTH,
parathyroid hormone; wPTH, whole parathyroid hormone; ULN,
upper limit of normal.
Bone Marker and Bone Histology Correlationrespectively.21,26 The sensitivity and speciﬁcity of
discriminating high and low bone turnover based on
these PTH values is shown in Table 4. The utility of
PTH level in differentiating high bone turnover from
nonhigh turnover using the iPTH cutoff for NKF-
KDOQI (.300 pg/mL) and KDIGO (.9 times the
upper limit of normal) had relatively high speciﬁcity,
with use of the KDIGO value being slightly more
speciﬁc. However, both guideline cutoff values had
low sensitivity. The positive and negative predictive
values for PTH according to KDIGO and
NKF-KDOQI guidelines are summarized in Table 5.
In summary, although there was signiﬁcant ROC-
based discrimination for iPTH plus bALP levels in
differentiating low from nonlow bone turnover and
high from nonhigh bone turnover, these biomarkers did
not reach acceptable levels of discrimination for use in
single-time-point diagnosis in an individual patient.
The other biomarkers did not add diagnostic value.
DISCUSSION
This study represents what is to our knowledge one
of the 2 largest bone biopsy studies ever reported,
with the goal to determine the usefulness of circu-
lating biomarker levels for predicting bone histopa-
thology in an international setting (the other was an
analysis of 630 bone biopsies23). For more than 30
years, prevention and treatment of the disturbances of
bone and mineral metabolism of CKD have focusedAm J Kidney Dis. 2016;67(4):559-566
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to treat hyperparathyroidism are used to improve bone
remodeling with the ultimate goal of reducing fracture
risk. The present study demonstrates that use of PTH
level to assess bone turnover continues to be the best
parameter of those tested.
Although PTH and bALP levels performed better
than the other parameters, our study demonstrated that
both biomarkers provided only suboptimal acceptable
discriminating ability for the assessment of bone
turnover because the AUROC was ,0.80. The com-
bination of PTH and bALP levels offered minimal
additional discrimination and one could argue that
bALP level alone was at least as good. This is
consistent with previous observations.27,28
In past studies, the discriminatory ability of PTH
level to predict bone turnover has been obtained by
using the Nichols iPTH assay, which is no longer
available. Currently available second-generation
immunometric PTH assays show variable detection
of PTH fragments in addition to iPTH, which has
been shown to modify the interpretation of “active”
PTH values. However, we did not ﬁnd clinical
differences in the AUROC using iPTH (second-
generation) compared to whole PTH (third-generation)
assays. These results are not surprising if one considers
that bonemetabolism in CKD is affected by an intricate
pathophysiologic process involving several humoral
and local factors besides PTH.
Current strategies have focused on the use of PTH
as a surrogate for bone turnover, and treatment is
mostly aimed at lowering PTH levels with vitamin D
receptor activators29 or calcimimetics.30 Because of
concerns about the oversuppression of bone remodel-
ing, the recent KDIGO clinical practice guideline
has broadened the range of target or goal PTH levels, in563
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Table 5. Utility of NKF-KDOQI and KDIGO iPTH Thresholds for Diagnostic Decision Making
NKF-KDOQIa KDIGOb
Sensitivity Specificity PPV NPV Sensitivity Specificity PPV NPV
Differentiating low from nonlow
turnover bone disease, or “When
do I stop therapy?”
68.5% 61.2% 71.6% 57.7% 65.7% 65.3% 73% 57%
Differentiating high from nonhigh
turnover bone disease, or “When
do I start therapy?”
58.0% 77.7% 34.8% 90% 37.0% 85.8% 34.9% 86.9%
Abbreviations: iPTH, intact parathyroid hormone; KDIGO, Kidney Disease: Improving Global Outcomes; NKF-KDOQI, National
Kidney Foundation–Kidney Disease Outcomes Quality Initiative; NPV, negative predictive value; PPV, positive predictive value.
aUsing serum iPTH, 150 pg/mL for lower and .300 pg/mL for upper threshold.
bUsing serum iPTH, 130 pg/mL for lower and .585 pg/mL for upper threshold (23 and 93 upper limit of normal for assay).
Sprague et alpart to reduce the risk of treating patients with low
turnover bone disease or to induce it, as shown by
bone histomorphometry, despite relatively high serum
PTH levels.21 Therefore, diagnostic accuracy of PTH
as a surrogate for bone turnover is of paramount
importance, although this study did not test the rec-
ommended use of trends to monitor therapy. In the
present study, bone biopsies with simultaneously ob-
tained and stored serum samples were analyzed to
determine the predictive value of PTH level for
assessment of renal osteodystrophy by bone histo-
morphometry. Due to controversies regarding PTH
assays and the variable results obtained from different
assays,19 biopsies were analyzed based on stored serum
collected at the time of the biopsy that was reanalyzed
for both iPTH, measured by chemiluminescence
immunoassay (Roche Elecsys 2010 Analyzer), and
whole PTH (ie, amino acids 1-84), measured by
immunoradiometric assay (Scantibodies Laboratories).
The pooling of specimens across the globe allowed
for adequate power to test PTH and combinations of
bone biomarkers. Based on an AUROC $ 0.70, serum
iPTH values situated in either the NKF-KDOQI iPTH
target ranges (150-300 pg/mL) or the KDIGO PTH
target ranges (.2 or ,9 times the upper limit of
normal) had relatively high speciﬁcity, but low sensi-
tivity to differentiate high turnover from nonhigh
turnover as assessed by bone histomorphometric
analysis.Measuring serumwhole PTH did not improve
speciﬁcity or sensitivity. Unfortunately, the addition of
bALP or other biomarkers did not prove to be clinically
useful beyond the diagnostic value of PTH in the
assessment of bone turnover. Consistent with other
studies, serum PTH levels correlated with bone turn-
over14,23,31-33; however, to date, PTH levels have not
been found to be a strong discriminator among low,
normal, and high bone turnover. The present analysis
demonstrates that iPTH can be used to discriminate low
turnover from nonlow turnover with iPTH values
consistent with those recommended by both NKF-
KDOQI and KDIGO (Table 4).21,26564
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lowering therapies. Clearly understanding when low
turnover bone disease is present without having to
rely on a bone biopsy would be very useful to reliably
guide therapy in clinical practice. The present study
found that measurement of whole PTH, but not iPTH,
using either clinical practice guideline cutoffs had
relatively high sensitivity, but not speciﬁcity for
discriminating low turnover from nonlow turnover
disease on bone biopsy. Using the iPTH assay and
KDIGO clinical practice guideline (Table 5), the
negative predictive value for discriminating low from
nonlow turnover to answer the question of when to
stop therapy was 57%, with a positive predictive
value of 73%. To answer the question “When do I
start therapy to treat high turnover bone disease?”
using the iPTH assay, the negative predictive value
for discriminating high from nonhigh turnover was
87%, with a positive predictive value of 35%. Thus,
the KDIGO range is reasonable, but far from ideal, to
help guide clinical practice.
The majority of individuals had low bone turnover.
Malluche et al23 evaluated 630 bone biopsies and
reported a similarly high percentage of patients with
low bone turnover (58% compared to 59% in the
present study) and low percentage with high turnover
(24% compared to 17% in present study). The sub-
stantial difference in the prevalence of high turnover
bone disease between studies may be due at least in
part to ethnicity. In the analysis by Malluche et al,
black participants were found to have a signiﬁcantly
higher prevalence of high turnover compared with
white participants, and they had a much larger pro-
portion of black patients than the present analysis
(14% vs 6%). Another potential difference is in the
choice of therapies, which differs by country.
In addition to the commonly used bone biomarker
PTH, we assessed the ability of bALP and P1NP
levels to provide additional diagnostic accuracy. Un-
fortunately, the inclusion of bALP level provided
only limited clinically nonsigniﬁcant added value toAm J Kidney Dis. 2016;67(4):559-566
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Bone Marker and Bone Histology Correlationthat of PTH, and P1NP did not improve the diagnostic
accuracy. Serum samples were of limited quantity
and thus assessments of the diagnostic performance
of ﬁbroblast growth factor 23, 25-hydroxyvitamin
D, sclerostin, tartrate-resistant acid phosphatase 5b
(TRAP-5b), and other newer biomarkers could not be
made.
A major limitation of the present study is its cross-
sectional design, which did not allow interpretation of
the therapeutic interventions that mitigate the rela-
tionship of bone turnover with PTH and other bio-
markers. Other limitations are the origin of samples
from only 4 countries (with potentially limited
generalizability), no data to address differences be-
tween ethnic and racial groups, high use of calcium-
based phosphate binders and low use of vitamin D
sterols, and low prevalence of patients with diabetes.
In addition, uncertain stability of frozen blood sam-
ples may have affected results. Further, with the
exception of the biopsies from Turkey, the other
participants were referred for biopsy to assist in
clinical management and therefore may not be
generalizable to all patients with end-stage kidney
disease. Finally, there was no analysis of parameters
of cortical bone, which appears to be preferentially
lost in patients with CKD and hyperparathyroidism.34
In conclusion, PTH measured by iPTH assay offers
a reasonable assessment of bone turnover and the
ability to discriminate high from nonhigh and low
from nonlow turnover based on either the NKF-
KDOQI or KDIGO targets for PTH. This was only
marginally improved with the addition of bALP and
was not affected by other biomarkers. Although the
AUROC , 0.7 is suboptimal, this is not a surprising
ﬁnding given the short half-life of PTH and the long
duration of a bone remodeling cycle. Because these
analyses could not determine whether evaluating
trends in PTH levels over time could guide thera-
peutic decisions, further prospective studies are
required. In the absence of performing a bone biopsy,
iPTH measurement probably remains the best clini-
cally available tool to discriminate the extremes of
bone turnover.
The purpose of this study was to evaluate the
diagnostic value of biomarkers to predict bone
turnover and not to test the validity of guidelines.
The guidelines were based on limited evidence,
which did not include bone biopsy studies. However,
the present data are consistent with recommendations
proposed by KDIGO in using PTH level for the
clinical assessment of bone turnover, especially at
the extremes of PTH values. Trending changes in
PTH levels, an issue that has not been assessed in
this or other studies, may improve diagnostic preci-
sion and provide better clinical guidance for the
treatment of secondary hyperparathyroidism, asAm J Kidney Dis. 2016;67(4):559-566
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emphasized that PTH exerts actions on many tissues
other than bone and that this study does not negate
the usefulness of monitoring PTH levels in dialysis
patients.35
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